TW200806671A - Polymorphic forms of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide - Google Patents

Polymorphic forms of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide Download PDF

Info

Publication number
TW200806671A
TW200806671A TW096111803A TW96111803A TW200806671A TW 200806671 A TW200806671 A TW 200806671A TW 096111803 A TW096111803 A TW 096111803A TW 96111803 A TW96111803 A TW 96111803A TW 200806671 A TW200806671 A TW 200806671A
Authority
TW
Taiwan
Prior art keywords
crystalline form
compound
methyl
solid
dihydro
Prior art date
Application number
TW096111803A
Other languages
English (en)
Chinese (zh)
Inventor
Sacha Ninkovic
Raymond Rynberg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200806671A publication Critical patent/TW200806671A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW096111803A 2006-04-04 2007-04-03 Polymorphic forms of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide TW200806671A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78935106P 2006-04-04 2006-04-04

Publications (1)

Publication Number Publication Date
TW200806671A true TW200806671A (en) 2008-02-01

Family

ID=38294083

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096111803A TW200806671A (en) 2006-04-04 2007-04-03 Polymorphic forms of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide

Country Status (6)

Country Link
EP (1) EP2004655A1 (es)
JP (1) JP2007277241A (es)
AR (1) AR060348A1 (es)
CA (1) CA2648369A1 (es)
TW (1) TW200806671A (es)
WO (1) WO2007113647A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN103703004B (zh) 2011-12-31 2016-06-29 百济神州有限公司 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮
US9328111B2 (en) 2011-12-31 2016-05-03 Beigene Ltd. Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
WO2023242974A1 (ja) 2022-06-15 2023-12-21 三菱電機株式会社 高周波スイッチ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1585749T1 (sl) * 2003-01-09 2008-10-31 Pfizer Derivati diazepinoindola kot inhibitorji kinaze

Also Published As

Publication number Publication date
AR060348A1 (es) 2008-06-11
WO2007113647A1 (en) 2007-10-11
JP2007277241A (ja) 2007-10-25
CA2648369A1 (en) 2007-10-11
EP2004655A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
US10189837B2 (en) Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
KR102710941B1 (ko) Fgfr 저해제의 결정형 및 이의 제조 방법
JP5714024B2 (ja) ３−（２，６−ジクロロ−３，５−ジメトキシ−フェニル）−１−｛６−［４−（４−エチル−ピペラジン−１−イル）−フェニルアミノ］−ピリミジン−４−イル｝−１−メチル−尿素の結晶形態およびその塩
JP2011515370A (ja) ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態
WO2018183712A1 (en) Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
CN107922348A (zh) 双环杂环酰胺衍生物
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
TW200806671A (en) Polymorphic forms of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-YL)-1-OXO-2,6-dihydro-1H-[1,2]diazepino[4,5,6-CD]indol-8-YL)acetamide
US20080262025A1 (en) Processes for the Preparation of Zolpidem and its Hemitartrate
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
KR20220008284A (ko) 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도
CN109111439A (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
JP6961348B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
JP2023531078A (ja) 化合物の結晶形態
AU2023206373A1 (en) Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile
CN114805371A (zh) 含2-氨基嘧啶大环类化合物及其制备方法和用途